Abbott Stock Jumps as Profit Forecast Rises: Strategic Acquisition Drives Growth

Shares of Abbott Laboratories (NYSE: ABT) surged after the healthcare products provider raised its full-year profit forecast. The company reported a 13% increase in second-quarter sales to $12.6 billion, driven by its $21 billion acquisition of cancer screening leader Exact Sciences. This strategic move expanded Abbott's preventive product portfolio, including Exact's market-leading noninvasive colorectal cancer test, Cologuard. Abbott's global diagnostics revenue jumped 42.3% to $3.1 billion, while medical devices revenue grew 9% to $5.9 billion, supported by an 11% rise in continuous glucose monitor sales. Adjusted earnings per share reached $1.31, exceeding Wall Street's expectation of $1.28. The company now projects full-year comparable sales growth of 6.5% to 7.5% and adjusted EPS between $5.45 and $5.60, up from previous guidance. Despite steady dividend increases over 54 years, investors may find higher-growth opportunities in other sectors.

Strategic Acquisition Fuels Financial Momentum

■The $21 billion Exact Sciences deal contributed to a 13% Q2 sales boost.

■Diagnostics revenue surged 42.3% to $3.1 billion.

■Medical devices revenue grew 9% to $5.9 billion, led by an 11% jump in continuous glucose monitors.

■Full-year EPS outlook raised to $5.45-$5.60, surpassing prior estimates.

While Abbott's acquisition and profit growth are commendable, markets may favor tech-focused equities with higher growth trajectories. Companies like ASML and TSMC, given their critical roles in semiconductor supply chains, remain poised for structural outperformance amid global tech demand.